IGI Logo

Strides Pharma Science is currently trading at Rs. 1377.50, up by 33.50 points or 2.49% from its previous closing of Rs. 1344.00 on the BSE.

The scrip opened at Rs. 1354.90 and has touched a high and low of Rs. 1394.95 and Rs. 1347.60 respectively. So far 6016 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1,394.95  on 06-Sep-2024 and a 52 week low of Rs. 452.75 on 12-Sep-2023.

Last one week high and low of the scrip stood at Rs. 1394.95 and Rs. 1325.40 respectively. The current market cap of the company is Rs. 12791.85 crore.

The promoters holding in the company stood at 25.86%, while Institutions and Non-Institutions held 45.28% and 28.87% respectively.

Strides Pharma Science’s step-down wholly owned subsidiary -- Strides Pharma Global Pte., Singapore, has received approval for the generic version of Theophylline Extended-Release Tablets, 300 mg and 450 mg, from the United States Food & Drug Administration (USFDA). The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), THEO-DUR, of Schering Corp. 

Theophylline extended-release tablets are indicated for the treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis. Theophylline Extended-Release Tablets, 300 mg and 450 mg have a combined market size of around $11.5 million, with the 300 mg dosage contributing around $10.8 million as per IQVIA. The Theophylline Extended-Release Tablets, 300 mg and 450 mg will be manufactured at the company’s flagship facility in KRS Gardens in Bangalore, India.

Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.